-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex reports ASCO data linking Trop-2, PTEN biomarkers to longer PFS in Reqorsa-treated NSCLC patients

PUBT·05/26/2026 12:05:50
Listen to the news
Genprex reports ASCO data linking Trop-2, PTEN biomarkers to longer PFS in Reqorsa-treated NSCLC patients
  • Genprex disclosed ASCO 2026-published clinical biomarker findings tied to its lead lung-cancer gene therapy candidate, Reqorsa.
  • Results were already presented via an abstract published for the 2026 ASCO Annual Meeting.
  • In a small dataset, certain tumor biomarker patterns aligned with longer time before disease progression in non-small cell lung cancer.
  • The same biomarker signals did not translate into a clear benefit signal in small cell lung cancer.
  • Management framed the readout as supporting more targeted patient selection in future development for Reqorsa in lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260800PR_NEWS_USPR_____DA66499) on May 26, 2026, and is solely responsible for the information contained therein.